Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
SAMIL PHARMACEUTICAL CO.,LTD |
End-of-day quote
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 6,280.00 KRW | -0.16% | +1.62% | -19.49% | |
| Sales 2022 | 180 B 139 M | Sales 2023 * | - | Capitalization | 109 B 84.17 M |
|---|---|---|---|---|---|
| Net income 2022 | -28.00 M -21,644 | Net income 2023 * | - | EV / Sales 2022 | 1,48x |
| Net Debt 2022 | 157 B 122 M | Net cash position 2023 * | - 0 | EV / Sales 2023 * | - |
| P/E ratio 2022 | -3 837x | P/E ratio 2023 * | Employees | 548 | |
| Yield 2022 | - | Yield 2023 * |
-
| Free-Float | 55.45% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.16% | ||
| 1 week | +1.62% | ||
| Current month | -0.16% | ||
| 1 month | -0.16% | ||
| 3 months | -13.26% | ||
| 6 months | -14.67% | ||
| Current year | -19.49% |
1 week
6 030.00
6 480.00
1 month
5 970.006 480.00
Current year
5 690.009 020.00
1 year
5 690.009 020.00
3 years
5 690.0010 636.36
5 years
4 545.4518 386.36
10 years
2 404.5529 000.00
| Managers | Title | Age | Since |
|---|---|---|---|
Sang-Jin Kim
CEO | Chief Executive Officer | 58 | - |
Seung-Bum Heo
CEO | Chief Executive Officer | 42 | - |
Cheong-Ha Choi
CTO | Chief Tech/Sci/R&D Officer | 51 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Seung-Bum Heo
CEO | Chief Executive Officer | 42 | - |
Kyung-Chul Oh
BRD | Director/Board Member | 59 | - |
Joon-Beom Huh
BRD | Director/Board Member | 38 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 5,201 M€ | +9.44% | - | |
| 0.00% | 2,233 M€ | +8.37% | - | |
| 0.00% | 2,723 M€ | +6.83% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-12-01 | 6,280.00 | -0.16% | 34,128 |
| 23-11-30 | 6,290.00 | +2.44% | 35,588 |
| 23-11-29 | 6,140.00 | -1.92% | 58,408 |
| 23-11-28 | 6,260.00 | +2.45% | 85,215 |
| 23-11-27 | 6,110.00 | -1.13% | 28,416 |
End-of-day quote Korea Stock Exchange, December 30, 2023
More quotes
SAMIL PHARMACEUTICAL CO., LTD is a Korea-based company mainly engaged in the manufacture of medicines. The Company's products portfolio consists of gastro-intestinal drugs such as antiulcerants, gastroprokinetic agents, digestive enzymes with nutrients and laxatives under the brand names of Plybutine, Gliptide and others; antipyretic, analgesic and anti-inflammatory agents under the brand name Brufen; nutritional supplements such as vitamins, minerals and immunosuppressants, and others including antigout agents, anti-parkinsonism agents and others. In addition, it is engaged in the provision of miscellaneous goods. The Company distributes its products within domestic market and to overseas markets. On November 29, 2013, it transferred its entire shares of a Korea-based company, which is engaged in the sale of medical products.
Sector
Pharmaceuticals
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -19.49% | 70 M $ | |
| +22.95% | 35 472 M $ | |
| +32.96% | 21 099 M $ | |
| 0.00% | 12 720 M $ | |
| +12.06% | 11 688 M $ | |
| -12.16% | 8 801 M $ | |
| +52.33% | 7 775 M $ | |
| -0.05% | 6 788 M $ | |
| -8.87% | 5 726 M $ | |
| +0.79% | 5 062 M $ |
